Cytogenetic Clonal Evolution in Patients with Chronic Myeloid Leukemia

Autor:	Yildiz Aydin, Şükriye Yilmaz, Zafer Baslar, Seniha Hacıhanefioğlu, Teoman Soysal, Burhan Ferhanoglu, Birsen Ülkü, S. Purisa, Ayhan Deviren, Yelda Tarkan-Argüden, Ayşe Çırakoğlu, Umit Ure, Gülgün S. Güven, Dilhan Kuru, Şeniz Öngören, Ahmet Emre Eskazan, Gürsel Çetin, Nukhet Tuzuner, M. Cem Ar
Rok vydání:	2009
Předmět:	medicine.medical_specialty Cytogenetics Myeloid leukemia Chromosome Imatinib Biology Somatic evolution in cancer Molecular biology hemic and lymphatic diseases Immunology medicine In patient Chronic phase CML Chromosome 21 Biotechnology medicine.drug
Zdroj:	Biotechnology & Biotechnological Equipment. 23:1515-1520
ISSN:	1314-3530 1310-2818
Popis:	Chronic myeloid leukaemia (CML) is a clonal haematological disease characterised by t(9;22)(q34;q11) which is called Philadelphia (Ph) chromosome. Highly improved haematological and cytogenetic results were obtained in chronic phase CML with the introduction of imatinib. Occurrence of additional cytogenetic abnormalities in Ph(+) cells is defined as clonal evolution (CE) and considered to be a preceding sign for acceleration. The most common additional chromosomal changes are +8, +Ph, i(17q), +19, -Y, +21, +17 and-7. The aims of this study were to delineate the occurrence pattern of cytogenetic clonal evolution in our cohort of CML patients and to investigate the impact on the course and prognosis of CML. Additional clonal chromosomal changes in Ph(+) cells were observed in 20 cases (19%). The abnormalities seen were monosomy 21 (%35), -17 (%30), -19 and +8 in (%25), -7, -8, -13, -15, -22, +Ph, and different marker chromosomes (%20), -Y, -12, -14, -16, -20 (%15), +Y, -10, -18 (%10), and -X, -3, -9...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b00bad229ed9921ee3d46b0e9c08daf9 https://doi.org/10.2478/v10133-009-0022-6 Zobrazit plný text záznamu